Table 3.
Comparison of continuous outcomes at baseline and follow-up in intervention and control groups while adjusting for clustering, baseline differences, and prespecified covariates*. Values are means (standard deviations) unless stated otherwise
| Variable | Valid No at baseline/follow-up | Baseline | Follow-up | Intracluster correlation coefficient | Mean difference (95% CI) | P value | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention group | Control group | Intervention group | Control group | Intervention group | Control group | ||||||
| Systolic blood pressure (mm Hg) | 442/360 | 451/405 | 136.3 (22.2) | 136.8 (21.2) | 133.8 (17.0) | 137.9 (19.3) | 0.057 | 3.31 (−1.02 to 7.63) | 0.13 | ||
| Diastolic blood pressure (mm Hg) | 442/360 | 451/405 | 78.4 (11.9) | 79.4 (11.3) | 77.4 (10.1) | 78.6 (10.4) | 0.045 | 0.17 (−2.16 to 2.51) | 0.88 | ||
| Total cholesterol concentration (mmol/l) | 424/342 | 436/391 | 4.4 (0.9) | 4.3 (0.9) | 4.2 (0.9) | 4.2 (0.9) | 0.062 | 0.13 (−0.03 to 0.30) | 0.11 | ||
| No of hospital admissions per patient | 440/415 | 452/435 | 0.3 (0.6)† | 0.4 (0.8)† | 0.4 (0.7)‡ | 0.5 (1.0)‡ | 0.017 | −0.15 (−0.01 to −0.29) | 0.03 | ||
| No of cardiovascular hospital admissions§ | 425 | 444 | NA | NA | 0.14 (0.5) | 0.23 (0.7) | 0.003 | −0.11 (−0.21 to −0.01) | 0.04 | ||
| No of other hospital admissions per patient | 425 | 444 | NA | NA | 0.24 (0.6) | 0.32 (0.7) | 0.000 | −0.06 (−0.16 to 0.04) | 0.22 | ||
| Primary continuous variables: | |||||||||||
| SF-12 physical component summary | 380/311 | 382/338 | 39.9 (11.6) | 39.2 (10.8) | 40.5 (11.1) | 38.8 (11.1) | 0.076 | −0.78 (−2.58 to 1.03) | 0.39 | ||
| SF-12 mental component summary | 380/311 | 382/338 | 49.5 (10.5) | 48.4 (11.1) | 49.6 (10.9) | 48.9 (11.7) | 0.054 | −0.02 (−2.40 to 2.35) | 0.98 | ||
NA=not applicable.
*See footnote to table 2 for relevant covariates.
†Over 12 months.
‡Over 18 months.
§Analysis of hospital admissions and practice visits carried out on adjusted end points rather than change over time, owing to different data collection intervals at baseline (12 months) and follow-up (18 months).